Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE -238.2%. (2018–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $167986 | $678299 | $3M | $26M | $437M | $11.6B | — | — | — |
| Enterprise Value | $-7990014 | $-7479701 | $-2328305 | $25M | $438M | $11.6B | — | — | — |
| P/E Ratio → | -0.02 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | 0.11 | — | — | — | — | — | — |
| P/B Ratio | 0.03 | 0.11 | 0.64 | 101.59 | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | -0.10 | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | -0.0% | — | — | — | — | — | — |
| Operating Margin | — | — | -36.5% | — | — | — | -1459.0% | — | — |
| Net Profit Margin | — | — | -36.4% | — | — | — | -2531.0% | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -238.2% | -238.2% | -382.5% | -5033.6% | — | — | -287.6% | -205.8% | -2819.8% |
| ROA | -166.0% | -166.0% | -188.8% | -780.9% | -1070.5% | -1586.2% | -96.8% | -141.0% | -674.7% |
| ROIC | — | — | — | — | — | — | — | — | — |
| ROCE | -236.6% | -236.6% | -377.6% | -4396.5% | — | — | -132.7% | -174.2% | -2820.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.03 | 0.05 | — | — | — | 0.11 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.36 | -1.22 | -6.93 | — | — | — | -1.08 | -4.01 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | -5.26 | -3.93 | -580.44 | -42.91 | -16.58 | — |
Net cash position: cash ($8M) exceeds total debt ($71000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.25 | 3.25 | 3.43 | 1.09 | 0.16 | 0.02 | 0.30 | 4.86 | 1.31 |
| Quick Ratio | 3.25 | 3.25 | 3.43 | 1.09 | 0.16 | 0.02 | 0.30 | 4.86 | 1.31 |
| Cash Ratio | 3.11 | 3.11 | 3.07 | 0.67 | 0.00 | 0.80 | 0.05 | 4.73 | 1.26 |
| Asset Turnover | — | — | 3.93 | — | — | — | 0.10 | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.6% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.6% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $98162 | $6546 | $1578 | $1160 | $11602 | $891 | $891 | $891 |
Clinical Trial Funding Shortfall
Based on reported figures, GRI's price-to-book ratio of 0.03 indicates that the market assigns negligible value to the company's tangible assets, reflecting deep skepticism regarding the clinical viability of its NKT cell modulation platform and the high probability of future equity dilution to sustain operations.
The extreme discount to book value suggests that investors are pricing the firm as a distressed asset rather than a growth-stage biotechnology company. This valuation implies that the market views the current intellectual property as having limited commercial optionality without a successful Phase II clinical readout.
As reported in financial statements, GRI's profitability remains deeply negative, with ROE fluctuating between -24.1% and -161.2% over the last ten quarters, underscoring the firm's total reliance on external capital to fund its non-revenue-generating research and development activities in the inflammatory disease space.
The absence of gross or operating margins confirms that the company has not yet achieved any commercial scale or product-market fit. Investors should interpret these persistent losses as a structural feature of the current development phase rather than a temporary operational inefficiency.
According to recent SEC filings, GRI's current ratio has exhibited extreme volatility, ranging from 1.09 to 14.21, which highlights the precarious nature of its liquidity position as the company consumes its cash reserves to advance its lead candidates through the regulatory pipeline.
The erratic nature of the current ratio suggests that liquidity is highly sensitive to the timing of capital raises rather than operational cash generation. This instability warrants close monitoring, as the firm lacks the internal cash flow to provide a consistent cushion against clinical trial cost overruns.
Based on the provided data, the most commonly misapplied metric for GRI is the price-to-earnings ratio, which is fundamentally irrelevant for a pre-revenue clinical-stage entity and obscures the critical importance of the cash runway ratio in determining the company's long-term survival and potential for shareholder dilution.
Using P/E ratios to evaluate a company with no revenue and negative earnings provides no insight into the underlying value of the clinical pipeline. Analysts should instead focus on the cash burn rate relative to the remaining liquidity to assess the probability of reaching the next clinical milestone.
Includes 30+ ratios · 8 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying GRI stock.
GRI Bio, Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
GRI Bio, Inc.'s return on equity (ROE) is -238.2%. The historical average is -278.5%.
Based on historical data, GRI Bio, Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.